Anthropic has described drug-development collaborations with six organizations alongside its own research programs. In one BigHat case, approximately 1,010 antibody variants were made and tested over about ten weeks, improving properties such as binding and stability in selected candidates. Claude also supported document review, experimental planning and operations, while Anthropic disclosed its acquisition of rare-muscle-disease startup Mithril Medicine. Most results are preclinical and reported by the company and its partners, not proof of patient benefit or eventual clinical-trial success.